Medical professionals
Empowering clinicians with pioneering research and treatment insights
We continue to discover, assess and develop new compounds and biologics with therapeutic and diagnostic promise for neurodegenerative diseases caused by protein aggregation.
Clinical trials
Clinical trials are critical to taking science from the laboratory to a point where we can help patients. Find out more about our trials and how they’ve advanced our understanding of how to treat neurodegenerative diseases.
Neurodegenerative disorders
Our groundbreaking drug could treat a range of conditions that share common pathological features.
Tau and tau pathology
Healthy tau protein is critical for stabilising cell structure in the brain, but can disrupt neuronal function if it misfolds.
Neurofilament Light Chain (NfL)
This biomarker for damaged brain cells can be a powerful tool for measuring and predicting disease progression.
Tau inhibition
Our investigational product, hydromethylthionine mesylate (HMTM), belongs to a class of drugs known as Tau Aggregation Inhibitors (TAIs). These work by preventing and dissolving tau aggregates, to preserve the normal tau function essential for a healthy brain.
Mild cognitive impairment (MCI)
Recognising MCI as an early predictor for dementia is critical to engaging patients and carers as early as possible.
Alzheimer’s disease
Discover the impact of our investigational drug, HMTM, on the progression of Alzheimer’s disease, from the results of clinical trials and programmes involving 3,000 participants.
Frontotemporal dementia (FTD)
Frontotemporal dementia and Alzheimer’s share a similar pathology but affect different regions of the brain. We are investigating the use of HMTM as a potential treatment for FTD.
Frequently Asked Questions (FAQs)
Learn more about TauRx, Alzheimer’s disease, and how our research could make a difference for people living with the condition.